

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
16 June 2005 (16.06.2005)

PCT

(10) International Publication Number
WO 2005/054236 A1

(51) International Patent Classification⁷: **C07D 471/04**,
519/00, C07K 5/00, C07H 21/00, A61P 35/00, A61K
31/4745

(74) Common Representative: **CRYSTAX PHARMACEU-
TICALS S.L.**; JUNGHANS, Claas, Josep Samitier 1-5,
E-08028 Barcelona (ES).

(21) International Application Number:
PCT/EP2004/013106

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.

(22) International Filing Date:
18 November 2004 (18.11.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
P200302821 20 November 2003 (20.11.2003) ES

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE,
SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

(71) Applicants (for all designated States except US): **CRY-
STAX PHARMACEUTICALS S.L.** [ES/ES]; Josep
Samitier 1-5, E-08028 Barcelona (ES). **CONSEJO SU-
PERIOR DE INVESTIGACIONES CIENTIFICAS**
[ES/ES]; Serrano, 113, 28006 Madrid (ES). **UNIVERSI-
TAT POLITÈCNICA DE CATALUNYA** [ES/ES]; Jordi
Girona, 31, E-8034 Barcelona (ES).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii)) for the following designation US
- of inventorship (Rule 4.17(iv)) for US only

(72) Inventors; and



(75) Inventors/Applicants (for US only): **AYMAMI BO-
FARULL, Juan** [ES/ES]; Universitat Politècnica de
Catalunya, Jordi Girona, 31, E-08034 Barcelona (ES).
COLL CAPELLA, Miquel [ES/ES]; Consejo Superior de
Investigaciones Cientificas, Serrano, 113, E-28006 Madrid
(ES). **LLEBARIA SOLDEVILA, Amadeo** [ES/ES];
Consejo Superior de Investigaciones Cientificas, Serrano,
113, E-28006 Madrid (ES). **NAVARRO MUÑOZ, Isabel**
[ES/ES]; Crystax Pharmaceuticals, S.L., Parc Científic de
Barcelona, Josep Samitier 1-5, E-08028 Barcelona (ES).

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: SUBSTITUTED QUINOLINES FOR THE TREATMENT OF CANCER



(57) Abstract: Compounds of
formula G_1-L-G_2 , where $-G_1$ is
a radical structurally close to
cryptolepine, $-L-$ is a single covalent
bond or a covalent linking biradical
selected from $(CH_2)_iNR''(CH_2)_j$ and
 $-(CH_2)_iNR'''(CH_2)_jNR'''(CH_2)_k-$,
 $-R''$ and $-R'''$ are radicals, same or
different, selected from the group
consisting of H and (C_1-C_3) -alkyl; i ,
 j and k are an integer from 1 to 3 and,

$-G_2$ is H or a radical structurally close to $-G_1$, are intercalators. They are compounds which intercalate between DNA base pairs, and are useful as therapeutic agents against cancer, as assess by an *in vitro* test of cytotoxicity with human leukemia cells Jurkat E6-1 and human carcinoma cells GLC-4. Preferred compounds are those where $-G_1$ is bonded to $-L-$ through a carbonyl amino and $-L-$ is $-(CH_2)_3NCH_3(CH_2)_3$ or $-(CH_2)_2NCH_3(CH_2)_3NCH_3(CH_2)_2-$ where $s = 2$ or 3. $-G_1$ is a radical selected from (IIa) y (IIb); $-G_2$ is a radical selected from H, a radical of formula (IIa), a radical of formula (IIb), the N-radical of 1,8-naphthalimide, the C4-radical of 2-phenylquinoline, and the C9-radical of acridine.